ABUS — ARBUTUS BIOPHARMA CORP

Ownership history in Aberdeen Group plc  ·  3 quarters on record

This page tracks every 13F SEC filing in which Aberdeen Group plc reported a position in ARBUTUS BIOPHARMA CORP (ABUS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.01% (2025 Q3)
Avg. % of fund
0.0%
First filed
2025 Q1
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 799,979 -182,548 -18.6% 0.01% $3.6M $4.54
2025 Q2 ADDED 982,527 +515,144 +110.2% 0.01% $3.0M $3.09
2025 Q1 INITIATED 467,383 — — 0.00% $1.6M $3.49
% of Fund (quarterly)    ABUS price (monthly, adj. close)

Other funds also holding ABUS

As of 2025 Q4 — sorted by position size

Whitefort Capital Management, LP 3Y 16.41% Rangeley Capital, LLC 3.36% ADAR1 Capital Management, LLC 1.89% Two Seas Capital LP 3Y 1.25% Western Standard LLC 3Y 7Y 1.13% STEMPOINT CAPITAL LP 0.81% BlackBarn Capital Partners LP 0.59% SHERBROOKE PARK ADVISERS LLC 3Y 0.35% AlphaCentric Advisors LLC 3Y 0.23% Murchinson Ltd. 3Y 0.21%
← Back to Aberdeen Group plc Holdings